BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17707061)

  • 1. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
    Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
    Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.
    Gregorian SK; Battisto JR
    Cancer Immunol Immunother; 1990; 31(6):325-34. PubMed ID: 2386978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model.
    Yamanaka K; Hara I; Nagai H; Miyake H; Gohji K; Micallef MJ; Kurimoto M; Arakawa S; Kamidono S
    Cancer Immunol Immunother; 1999 Sep; 48(6):297-302. PubMed ID: 10473804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
    Hwang KS; Cho WK; Yoo J; Yun HJ; Kim S; Im DS
    BMC Cancer; 2005 May; 5():51. PubMed ID: 15910693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
    Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
    Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.
    Iwanuma Y; Kato K; Yagita H; Okumura K
    Cancer Immunol Immunother; 1995 Jan; 40(1):17-23. PubMed ID: 7828164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
    Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH
    Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis.
    Harada M; Kotani H; Iida Y; Tanino R; Minami T; Komohara Y; Yoshikawa K; Uemura H
    Cancer Sci; 2024 May; 115(5):1405-1416. PubMed ID: 38413363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
    Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression.
    Gregorian SK; Battisto JR
    Cancer Immunol Immunother; 1990; 31(6):335-41. PubMed ID: 1974826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
    Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
    Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.
    Lu X; Kallinteris NL; Li J; Wu S; Li Y; Jiang Z; Hillman GG; Gulfo JV; Humphreys RE; Xu M
    Cancer Immunol Immunother; 2003 Oct; 52(10):592-8. PubMed ID: 12827305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
    Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
    Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
    Nishimatsu H; Takeuchi T; Ueki T; Kajiwara T; Moriyama N; Ishida T; Li B; Kakizoe T; Kitamura T
    Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.
    Salup RR; Wiltrout RH
    Cancer Immunol Immunother; 1986; 22(1):31-6. PubMed ID: 3486715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo.
    Li Q; Li L; Shi W; Jiang X; Xu Y; Gong F; Zhou M; Edwards CK; Li Z
    Cancer Immunol Immunother; 2006 Dec; 55(12):1470-9. PubMed ID: 16555058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362.
    Utsugi T; Dinney CP; Killion JJ; Fidler IJ
    Cancer Immunol Immunother; 1991; 33(6):375-81. PubMed ID: 1878891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
    Fujihara A; Kurooka M; Miki T; Kaneda Y
    Cancer Immunol Immunother; 2008 Jan; 57(1):73-84. PubMed ID: 17602226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.